{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:27:11Z","timestamp":1758040031911,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1053\/hj.1999.v138.a100462","type":"journal-article","created":{"date-parts":[[2004,7,28]],"date-time":"2004-07-28T10:40:39Z","timestamp":1091011239000},"page":"S297-S306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S","title":["Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy"],"prefix":"10.1053","volume":"138","author":[{"given":"Nadine B","family":"Juran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/hj.1999.v138.a100462_BIB1","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199610243351707","article-title":"Advances in coronary angioplasty","volume":"335","author":"Bittl","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0735-1097(88)90082-4","article-title":"In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures","volume":"11","author":"Ellis","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/01.CIR.82.3.739","article-title":"Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry","volume":"82","author":"Detre","year":"1990","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0002-9149(91)90555-Y","article-title":"Immediate and short-term results of a 1988-1989 coronary angioplasty registry","volume":"67","author":"Stammen","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.CIR.83.3.927","article-title":"Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up","volume":"83","author":"de Feyter","year":"1991","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/0735-1097(92)90272-O","article-title":"Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile","volume":"19","author":"Lincoff","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0002-9149(87)90797-1","article-title":"Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty","volume":"59","author":"Simpfendorfer","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.CIR.77.2.372","article-title":"Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty","volume":"77","author":"Ellis","year":"1988","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.CIR.82.4.1193","article-title":"Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection","volume":"82","author":"Ellis","year":"1990","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB10","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/0735-1097(92)90631-V","article-title":"Lesion morphology and coronary angioplasty: current experience and analysis","volume":"19","author":"Myler","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"suppl L","key":"10.1053\/hj.1999.v138.a100462_BIB11","doi-asserted-by":"crossref","first-page":"L97","DOI":"10.1093\/eurheartj\/16.suppl_L.97","article-title":"Coronary intervention: risk stratification and management of abrupt coronary occlusion","volume":"16","author":"de Feyter","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1053\/hj.1999.v138.a100462_BIB12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199506083322306","article-title":"Platelet glycoprotein IIb\/IIIa receptors in cardiovascular medicine","volume":"332","author":"Lefkovits","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB14","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","author":"CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.a100462_BIB16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.a100462_BIB17","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB18","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina","volume":"97","author":"PARAGON Investigators","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non\u2013Q-wave myocardial infarction","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB22","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1161\/01.CIR.91.12.2882","article-title":"Bleeding complications with the chimeric antibody to platelet glycoprotein IIb\/IIIa integrin in patients undergoing percutaneous coronary intervention","volume":"91","author":"Aguirre","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI110973","article-title":"A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and\/or IIIa","volume":"72","author":"Coller","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1053\/hj.1999.v138.a100462_BIB24","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","article-title":"Pharmacodynamics of chimeric glycoprotein IIb\/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty","volume":"90","author":"Tcheng","year":"1994","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB25","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/0735-1097(95)00391-6","article-title":"Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb\/IIIa receptors","volume":"26","author":"Kleiman","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB26","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2165\/00003495-199448040-00007","article-title":"Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease","volume":"48","author":"Faulds","year":"1994","journal-title":"Drugs"},{"first-page":"1627","article-title":"REOPRO (abciximab)","year":"1999","key":"10.1053\/hj.1999.v138.a100462_BIB28"},{"key":"10.1053\/hj.1999.v138.a100462_BIB29","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S0735-1097(96)00417-2","article-title":"Role of platelets in restenosis after percutaneous coronary revascularization","volume":"28","author":"Le Breton","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.ATV.17.3.528","article-title":"7E3 monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1","volume":"17","author":"Simon","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1749-6632.1991.tb43703.x","article-title":"Monoclonal antibodies to platelet glycoprotein IIb\/IIIa as antithrombotic agents","volume":"614","author":"Coller","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/hj.1999.v138.a100462_BIB32","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/01.CIR.95.4.809","article-title":"Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy","volume":"95","author":"Berkowitz","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB33","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9149(99)80345-2","article-title":"Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb\/IIIa inhibitor during percutaneous coronary intervention","volume":"76","author":"Harrington","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB34","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/S0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","article-title":"Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high risk patients undergoing coronary angioplasty","volume":"27","author":"Kereiakes","year":"1996","journal-title":"J Am Coll Cardiol"},{"first-page":"1721","article-title":"AGGRASTAT (tirofiban hydrochloride)","year":"1999","key":"10.1053\/hj.1999.v138.a100462_BIB36"},{"key":"10.1053\/hj.1999.v138.a100462_BIB37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0002-9343(87)90004-0","article-title":"Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy","volume":"82","author":"Landefeld","year":"1987","journal-title":"Am J Med"},{"key":"10.1053\/hj.1999.v138.a100462_BIB39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9149(97)00796-0","article-title":"Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial","volume":"81","author":"Blankenship","year":"1998","journal-title":"Am J Cardiol"},{"issue":"suppl I","key":"10.1053\/hj.1999.v138.a100462_BIB40","first-page":"I","article-title":"Decreased vascular access site bleeding after coronary intervention with abciximab in the EPILOG vs the EPIC trial [abstract]","volume":"96","author":"Blankenship","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB41","doi-asserted-by":"crossref","first-page":"21B","DOI":"10.1016\/S0002-9149(97)00573-0","article-title":"Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial","volume":"80","author":"Tcheng","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100462_BIB42","doi-asserted-by":"crossref","first-page":"29B","DOI":"10.1016\/S0002-9149(97)00574-2","article-title":"Primary and secondary safety endpoints from IMPACT II","volume":"80","author":"Kleiman","year":"1997","journal-title":"Am J Cardiol"},{"issue":"suppl I","key":"10.1053\/hj.1999.v138.a100462_BIB43","first-page":"I","article-title":"The incidence and analysis of bleeding and vascular complications following percutaneous coronary interventional procedures [abstract]","volume":"88","author":"Brown","year":"1993","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001786-199304000-00009","article-title":"From unit-based quality assurance to multidisciplinary continuous quality improvement in the coronary care unit","volume":"7","author":"Laughon","year":"1993","journal-title":"J Nurs Care Qual"},{"issue":"suppl I","key":"10.1053\/hj.1999.v138.a100462_BIB45","first-page":"I","article-title":"Sandbags do not prevent complications after catheterization [abstract]","volume":"90","author":"Christensen","year":"1994","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100462_BIB46","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4037\/ajcc1996.5.6.442","article-title":"Survey of current practice patterns for percutaneous transluminal coronary angioplasty","volume":"5","author":"Juran","year":"1996","journal-title":"Am J Crit Care"},{"key":"10.1053\/hj.1999.v138.a100462_BIB47","article-title":"Nursing interventions to decrease femoral access site bleeding after percutaneous coronary intervention","author":"Juran","year":"1999","journal-title":"J Crit Care Nurs"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:03:40Z","timestamp":1757567020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870399004512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["S0002870399004512"],"URL":"https:\/\/doi.org\/10.1053\/hj.1999.v138.a100462","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/hj.1999.v138.a100462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}